Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AACR-ADOPT-GEA
NCT07290985Phase 2Recruiting
- Sponsor
- American Association for Cancer Research
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of zanidatamab, zolbetuximab, tislelizumab in gastroesophageal adenocarcinoma, sponsored by American Association for Cancer Research. Started Jul 2026; status: recruiting.
02
Drugs
zanidatamabzolbetuximabtislelizumab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT07290985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290985.